SPLITOAK STRATEGIES LLC for CARIS LIFE SCIENCES, INC.
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Medical/Disease Research/Clinical Labs MED
Coverage and reimbursement of Next Generation Sequencing and other precision medicine technologies. Date of Service requirements, PAMA implementing regulations reforming clinical lab payment policy.
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMY JENSEN New | Special Assistant to the President for Legislative Affairs (2003-2005); Assistant to the Speaker for Policy (1999-2001) |
Medicare/Medicaid MMM
Coverage and reimbursement of Next Generation Sequencing and other precision medicine technologies. Date of Service requirements, PAMA implementing regulations reforming clinical lab payment policy.
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMY JENSEN New | Special Assistant to the President for Legislative Affairs (2003-2005); Assistant to the Speaker for Policy (1999-2001) |
Health Issues HCR
Coverage and reimbursement of Next Generation Sequencing and other precision medicine technologies. Date of Service requirements, PAMA implementing regulations reforming clinical lab payment policy.
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMY JENSEN New | Special Assistant to the President for Legislative Affairs (2003-2005); Assistant to the Speaker for Policy (1999-2001) |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| CARIS LIFE SCIENCES LTD | Cayman Islands | United States | 100.0% | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.